Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC

被引：0
|
作者：
Law, H. [1 ]
King, J. C. [1 ]
Lin, H. M. [2 ]
Curran, E. [2 ]
Wiens, J. [1 ]
Cruz, L. [3 ]
Blender, J. [4 ]
Venanzi, E. S. [4 ]
Schenk, E. [5 ]
Lin, J. J. [6 ]
机构：
[1] GO2 Lung Canc, Washington, DC USA
[2] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] ALK Posit Inc, Atlanta, GA USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] Mass Gen Canc Ctr, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
care-planning; self-management; 4R;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA05.04
引用
收藏
页码：S113 / S114
页数：2
相关论文
共 50 条
  • [31] Brigatinib in the first-line treatment of ALK plus metastatic NSCLC: safety and efficacy
    Bronte, Giuseppe
    Cafaro, Alessandro
    Pasini, Luigi
    Priano, Ilaria
    Andrikou, Kalliopi
    Cravero, Paola
    Burgio, Marco Angelo
    Delmonte, Angelo
    Crino, Lucio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 809 - 817
  • [32] ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (11) : 720 - 720
  • [33] Real-World Patient Characteristics, Testing and Treatment Patterns of ALK plus NSCLC
    Gubens, M.
    Wong, W.
    Wu, N.
    Chu, L.
    Schulze, K.
    Illei, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1894 - S1895
  • [34] Resensitizing Refractory ALK plus NSCLC: A Case Study
    Poh, Alissa
    CANCER DISCOVERY, 2016, 6 (03) : 220 - +
  • [35] Alectinib superior to chemotherapy in advanced ALK plus NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (06): : E285 - E285
  • [36] Phase 2 Study of Ceritinib in Patients with ALK plus NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
    Horinouchi, H.
    Maemondo, M.
    Hida, T.
    Takeda, M.
    Hotta, K.
    Hirai, F.
    Kim, Y.
    Matsumoto, S.
    Mitsudomi, T.
    Seto, T.
    Moizumi, S.
    Tokushige, K.
    Hatano, B.
    Nishio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1951 - S1952
  • [37] The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC
    Gately, Kathy
    O'Flaherty, John
    Cappuzzo, Frederico
    Pirker, Robert
    Kerr, Keith
    O'Byrne, Kenneth
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (01) : 1 - 7
  • [38] ALK inhibitors in the treatment of advanced NSCLC
    Gridelli, Cesare
    Peters, Solange
    Sgambato, Assunta
    Casaluce, Francesca
    Adjei, Alex A.
    Ciardiello, Fortunato
    CANCER TREATMENT REVIEWS, 2014, 40 (02) : 300 - 306
  • [39] MET and ALK as Targets for the Treatment of NSCLC
    Capelletti, M.
    Gelsomino, F.
    Tiseo, M.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (24) : 3914 - 3932
  • [40] Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC
    Somasundaram, Aswin
    Socinski, Mark A.
    Burns, Timothy F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (18) : 2693 - 2708
12345